The Department of Health said it will coordinate the supply of medicine for the treatment of leukemia patients, after the only pharmaceutical company in Taiwan that manufactures the medicine ceased its production. Liao Chi-chou,
director of the DOH Bureau of Medical Affairs, said the department has contacted
all hospitals in Taiwan in order obtain information on their stock of the drug
6-mercaptopurine (6-MP) and to determine whether is enough to meet the demand
of the 400 patients in Taiwan who need to take the medicine on a daily basis.
Taiwan
Headlines
Simplifying Global Compliance
Recommended Products
GMP Inspection Preparation Checklist: A Tool for Internal Auditing
This management report includes more than 650 items organized in three sections covering all aspects of quality manufacturing.
Biological Risk Evaluation and Management for Medical Devices
Report shows how the FDA incorporates the two ISO standards in its medical device development policy, how the EU version of the two standards differs in significant ways and how the EU Medical Device Regulation may require further changes in the European standards.
Editor's Picks
CoreLink’s 3D Anterior Lumbar Approved by FDA
The implant allows for better imaging by minimizing material density.
Endo Resumes Lawsuit Against FDA Over Bulk Drug Compounding Decree
The company claimed the agency’s handling of bulk compounding laws violates the 2013 Drug Quality and Security Act, treating the laws as non-binding guidance rather than a legal mandate.